Format
Sort by
Items per page

Send to

Choose Destination

Best matches for NAFLD probiotics:

Pediatric NAFLD: the Future role of Patient-Tailored Probiotics Therapy. Putignani L et al. J Pediatr Gastroenterol Nutr. (2016)

Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. Sáez-Lara MJ et al. Int J Mol Sci. (2016)

The role of the gut microbiota in NAFLD. Leung C et al. Nat Rev Gastroenterol Hepatol. (2016)

Search results

Items: 1 to 20 of 223

1.

A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption.

Jang HR, Park HJ, Kang D, Chung H, Nam MH, Lee Y, Park JH, Lee HY.

Exp Mol Med. 2019 Aug 13;51(8):95. doi: 10.1038/s12276-019-0293-4.

PMID:
31409765
2.

Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.

Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG.

Aliment Pharmacol Ther. 2019 Aug 2. doi: 10.1111/apt.15416. [Epub ahead of print] Review.

PMID:
31373710
3.
4.

Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention.

Mouzaki M, Loomba R.

Therap Adv Gastroenterol. 2019 Jun 23;12:1756284819858470. doi: 10.1177/1756284819858470. eCollection 2019. Review.

5.

Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions?

Knudsen C, Neyrinck AM, Lanthier N, Delzenne NM.

Curr Opin Clin Nutr Metab Care. 2019 Sep;22(5):393-400. doi: 10.1097/MCO.0000000000000584.

PMID:
31219825
6.

Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis.

Liu L, Li P, Liu Y, Zhang Y.

Dig Dis Sci. 2019 Jun 15. doi: 10.1007/s10620-019-05699-z. [Epub ahead of print] Review.

PMID:
31203554
7.

Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.

Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M.

Curr Obes Rep. 2019 Sep;8(3):317-332. doi: 10.1007/s13679-019-00352-2. Review.

PMID:
31175629
8.

Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota.

Li Y, Li J, Su Q, Liu Y.

Food Funct. 2019 Jun 19;10(6):3637-3649. doi: 10.1039/c9fo00195f.

PMID:
31165837
9.

Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.

Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA.

Am J Clin Nutr. 2019 May 24. pii: nqz042. doi: 10.1093/ajcn/nqz042. [Epub ahead of print]

PMID:
31124558
10.

Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).

Duarte SMB, Stefano JT, Oliveira CP.

Ann Hepatol. 2019 May - Jun;18(3):416-421. doi: 10.1016/j.aohep.2019.04.006. Epub 2019 Apr 16. Review.

11.

The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis.

Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ.

Eur J Gastroenterol Hepatol. 2019 Jun;31(6):703-715. doi: 10.1097/MEG.0000000000001371.

PMID:
31009401
12.

Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease.

Ahn SB, Jun DW, Kang BK, Lim JH, Lim S, Chung MJ.

Sci Rep. 2019 Apr 5;9(1):5688. doi: 10.1038/s41598-019-42059-3.

13.

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials.

Koutnikova H, Genser B, Monteiro-Sepulveda M, Faurie JM, Rizkalla S, Schrezenmeir J, Clément K.

BMJ Open. 2019 Mar 30;9(3):e017995. doi: 10.1136/bmjopen-2017-017995.

14.

Intestinal microbiome as a novel therapeutic target for local and systemic inflammation.

Uchiyama K, Naito Y, Takagi T.

Pharmacol Ther. 2019 Jul;199:164-172. doi: 10.1016/j.pharmthera.2019.03.006. Epub 2019 Mar 12. Review.

PMID:
30877020
15.

Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease.

Kim JC, Jeon JY, Yang WS, Kim CH, Eom DW.

Curr Pharm Biotechnol. 2019;20(3):222-231. doi: 10.2174/1389201020666190311143554.

PMID:
30854954
16.

Microbial Population Changes and Their Relationship with Human Health and Disease.

Álvarez-Mercado AI, Navarro-Oliveros M, Robles-Sánchez C, Plaza-Díaz J, Sáez-Lara MJ, Muñoz-Quezada S, Fontana L, Abadía-Molina F.

Microorganisms. 2019 Mar 3;7(3). pii: E68. doi: 10.3390/microorganisms7030068. Review.

17.

The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD.

Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2019 Feb 25;7(1). pii: E27. doi: 10.3390/diseases7010027. Review.

18.

Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.

Suk KT, Kim DJ.

Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25. Review.

PMID:
30791767
19.

Protection of hepatocyte mitochondrial function by blueberry juice and probiotics via SIRT1 regulation in non-alcoholic fatty liver disease.

Ren T, Zhu L, Shen Y, Mou Q, Lin T, Feng H.

Food Funct. 2019 Mar 20;10(3):1540-1551. doi: 10.1039/c8fo02298d.

PMID:
30785444
20.

Mesenteric lymph node CD4+ T lymphocytes migrate to liver and contribute to non-alcoholic fatty liver disease.

Su L, Wu Z, Chi Y, Song Y, Xu J, Tan J, Cong X, Liu Y.

Cell Immunol. 2019 Mar;337:33-41. doi: 10.1016/j.cellimm.2019.01.005. Epub 2019 Jan 28.

PMID:
30770094

Supplemental Content

Loading ...
Support Center